Compare NAVI & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | IVA |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | France |
| Employees | 670 | 77 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.4M | 883.8M |
| IPO Year | N/A | N/A |
| Metric | NAVI | IVA |
|---|---|---|
| Price | $7.84 | $3.50 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $10.00 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.3M | 909.6K |
| Earning Date | 04-29-2026 | 03-30-2026 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $76.23 | N/A |
| Revenue Next Year | $15.73 | $751.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.33 | $2.94 |
| 52 Week High | $16.07 | $7.98 |
| Indicator | NAVI | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 28.48 |
| Support Level | $7.33 | N/A |
| Resistance Level | $8.64 | $4.67 |
| Average True Range (ATR) | 0.33 | 0.27 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 41.08 | 2.97 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.